In medical humanitarian assistance, the diagnosis of diseases plays a crucial role. Laboratory investigations are one of the main diagnostic tools utilized in M é decins Sans Fronti è res ' (MSF) programs. Currently MSF supports and/ or operates more than 130 laboratories in approximately 45 countries. The variety of analysis offered depends largely on the context of the program and the availability of context adapted tools and ranges from sophisticated laboratories specializing in tuberculosis culture to small laboratories within a primary health care program or operating as mobile clinics. The largest laboratories in MSF are found in programs with the main objective to diagnose, treat and monitor patients with tuberculosis and/or human immunodefi ciency virus. Other MSF programs are either disease-specifi c (e.g., malaria, Chagas, kala azar or visceral leishmaniasis, sleeping sickness, malnutrition, sexually transmitted infections) or are integrated in primary or secondary health care structures.
Introduction
The delivery of laboratory services in resource-limited settings (RLS), especially in sub-Saharan Africa, confronts us with major diffi culties (Figure 1 B) . These challenges include not only the disease burden but also cost, human resource shortages, poor infrastructure, climate, poor education, access to health care and political factors such as migration and instability. Technical solutions have been developed to help overcome some of these challenges, often as a result of collaborative efforts by diagnostic device developers, nongovernmental organizations (NGOs) and the World Health Organization (WHO). In the past, new technologies such as molecular testing was considered too high-tech for RLS but simplifi ed solutions have become more widely available ( Table 1 ) .
The WHO ' s ASSURED criteria outline the ideal characteristics for the design of a diagnostic test for RLS as Affordable, Sensitive, Specifi c, User-friendly, Rapid and robust, Equipment-free, and Deliverable (ASSURED) to those in need (1) . Although originally developed by the WHO ' s Sexually Transmitted Diseases Diagnostics Initiative (SDI), the ASSURED criteria have been used for other diseases as well, summarizing useful criteria for effective diagnostic tools for diseases faced in RLS.
Equipment manufacturers have the responsibility for making simple, low-cost and robust equipment available to those countries who cannot afford to pay Western prices. This article aims to summarize some of the most important challenges in offering laboratory services in RLS, offer some lessons learned and highlight new technologies which have just emerged or about to be commercialized and were especially developed for use in RLS.
Mortality, disease burden and poverty in resource-limited settings
A few facts shall outline the needs of diagnosis and disease monitoring in RLS: life expectancy in the African region is 54 compared to 75 in the European region (2) . In 2004, worldwide 2.6 million deaths occurred in people between the ages of 10 and 24 years; 97 % of these occurred in RLS (3) .
In 2009, the mortality due to human immunodefi ciency virus/acquired immunodefi ciency syndrome (HIV/AIDS) was 177/100,000 in the African region and 10/100,000 in the European region. The tuberculosis (TB) mortality among HIV negatives was 52/100,000 in the African region, 27/100,000 in the south-east Asian region and 7/100,000 in the European region. The mortality due to malaria was 94/100,000 in the African region and 2.9 in the south-east Asian region. The number of physicians per 10,000 is 2.3 in the African region compared to 33.3 in the European region. More than 80 % of the world ' s population live on < $10 (US) per day (4) . 
HIV diagnosis and monitoring
In 2009, a total of 33.3 million people were living with HIV of which 2.5 million were children under 15 years of age. During the same year 2.6 million were newly infected and 1.8 million died of HIV/AIDS (5) .
In RLS HIV in adults is diagnosed with lateral-fl ow immunoassays (LFIs), mostly in a serial testing approach (6) . This approach maybe cost-effective but it has shown that low sensitivity and/or specifi city can be encountered (7 -11) . In various projects MSF decided to confi rm testing carried out on LFIs with an indirect solid-phase enzyme immunoassay (EIA), the ImmunoComb ® II HIV 1&2 CombFirm (Orgenics, Yavne, Israel). This test separates fi ve antigen specifi c areas for the gag (group-specifi c antigens), env (envelope) and pol (polymerase) region of the virus. The ' gag ' gene encodes information for the internal structures of the virus, the ' env ' gene for different surface proteins and the ' pol ' gene encodes for internal proteins, i.e., enzymes taking part in the integration and replication of the virus. The ImmunoComb ® II HIV 1&2 CombFirm is interpreted taking separate reactions to each of the fi ve antigen specifi c areas into account, rather than having two or three antigens combined in one spot or line as classical LFI for HIV screening do. The separation of reactions to the different areas of the virus allows for picking up crossreactions that are due to one antigen only, which would lead to false positive results when using a typical HIV LFI (9) .
Early infant diagnosis (EID) is even more complex as maternal antibodies can be passed to the infant by breastfeeding and cause a positive reaction on tests detecting antibodies. A well working method for EID, the ultrasensitive p24 antigen detection assay, has been developed by Perkin Elmer (Waltham, MA, USA). The test has been evaluated on several occasions and quality of evidence on its accuracy has been considered high by the WHO (12 -16) . Unfortunately, this test is not commercialized by Perkin Elmer and only available for research purposes as it is not registered as in vitro diagnostic. Discussions with Perkin Elmer have so far been unsuccessful in lobbying for commercialization of this product. The test is relatively simple to perform and could be carried out at a district or reference laboratory and even a protocol for elution from dried blood spots could be developed to ensure access for remote settings as well. The infants of the estimated 1,240,000 HIV positive mothers in need for anti-retroviral for PMTCT would benefi t from early infant diagnosis (17) .
However, an even more suitable test for remote settings is currently under fi eld validation: a lateral fl ow assay, with a preparatory heating step to disrupt immune complexes due to maternal antibodies, developed by the Northwestern University (Chicago, IL, USA) (18, 19) .
Currently, the most commonly used alternative is the detection of HIV by deoxyribonucleic acid polymerase chain reaction (DNA-PCR) which requires complex analyzers, a well equipped and clean laboratory and excellent trained staff. These are conditions not found in remote and underresourced settings, thus MSF decided to collect dried blood spots (DBS) which are then eluted at a reference laboratory where the DNA-PCR testing for HIV is carried out. But even when using sensitive DNA-PCR technique we are uncertain whether all early infant infections are detected. If mother and child are taking anti-retroviral therapy for prevention of mother to child transmission (PMTCT) the viral load in the infant may be lower than the detection level of the DNA-PCR and an infection may be missed.
Staging and progression of disease is done using CD4 cell counts and viral load (VL) measurements (Figure 2 D) . In 2010, the fi rst point-of-care CD4 analyzer, Pima TM CD4 (Alere Inc., Waltham, MA, USA), became commercially available. MSF purchased about 30 machines which are now in use in about 10 countries. Unfortunately, the price of each cartridge is quite high (approx. 6 USD per single use cartridge) and a high error frequency with aborted analysis of up to 14 % when used on capillary samples make the device less attractive in RSL as it increases cost further and requires higher educated staff (20) . In addition the analyzer cannot measure total lymphocyte counts, thus is not usable for monitoring in children where CD4 % are required. However, products under development such as the Daktari TM CD4 Counter (Daktari Diagnostics Inc., Cambridge, MA, USA), the MBio ™ Diagnostics CD4 system (MBio Diagnostics, Boulder, CO, USA), Zyomyx CD4 counter (Zyomyx, Hayward, CA, USA), the CD4 counter developed by the Burnet Institute (Melbourne, Australia) and the CD4 Point-of-Care Technology (BD Biosciences, Franklin Lakes, NJ, USA) may be promising alternatives and will also contribute to a competition on the CD4 point-of-care analyzer market with hopefully the effect of further price reductions to make CD4 cell monitoring widely available (20) .
Viral load access is still scarce in MSF programs and is currently not carried out on a routine basis, only targeted, when treatment failure is suspected. For this purpose DBS are collected and sent to an external laboratory for elution and analysis ( Figure 1A) .
In 2011, MSF implemented one of the few VL platforms in its program in Thyolo, Malawi. The lessons learned are long and include topics like the selection of the platform, additional equipment required, space, construction plans, human resources, standard operating procedures, quality control, equipment maintenance and electricity supply, to just name a few. The use of high-tech methods such as viral load in its current form will always include massive challenges and with upcoming simplifi ed technologies these will be reduced. Promising VL simplifi ed platforms to be commercialized in the coming 1 -2 years are the Alere NAT system (Alere Inc., Waltham, MA, USA), the Liat Analyzer (IQuum, Marlborough, MA, USA), SAMBA (Diagnostics for the Real World, Sunnyvale, CA, USA), GeneXpert ® System (Cepheid, Sunnyvale, CA, USA) and the rapid RT-PCR testing platform under development by the Northwestern Global Health Foundation (Chicago, IL, USA) and Quidel Cooperation (Santa Clara, CA, USA) (21) .
Tuberculosis
In 2009, globally there were an estimated 9.4 million incident TB cases (22) . Of these 11 % -13 % were HIV-positive. Of the TB cases in HIV-positives approximately 80 % occurred in the African region (22) (Figure 1C) .
In 2009, an estimated 1.3 million TB deaths occurred among HIV-negative cases. In addition, there were an estimated 0.4 million deaths among incident TB cases that were HIV-positive, thus in total, approximately 1.7 million people died of TB in 2009. In 2008, 440,000 cases of multi-drug resistant TB (MDR-TB) were estimated and by July 2010, 58 countries and territories had reported at least one case of extensively drug-resistant TB (XDR-TB) (22) . The diagnosis of smear-negative and MDR-TB requires complex culture settings, highly unsuitable, slow and costly for RLS.
The GeneXpert ® system (Cepheid, Sunnyvale, CA, USA) and their MTB/Rif assay for the diagnosis of TB and rifampicin resistance was endorsed by the WHO in December 2010 as the initial diagnostic test in settings characterized by high prevalence of multi-drug resistant MDR-TB and HIV ( Figure 2C ). The GeneXpert system allows a rapid TB diagnosis (turn-around-time < 2 h) and includes testing for resistance to rifampicin. The test integrates and automates within one cartridge the three processes required for realtime PCR-based molecular testing of TB: sample preparation, amplifi cation, and detection. Studies have demonstrated good performance of this test on pulmonary samples, with a sensitivity and specifi city approaching that of culture, considered the gold standard for TB diagnosis (23) . The system also shows favorable results for the diagnosis of some of forms of extrapulmonary TB (24) . MSF participated in the multicentric demonstration study of this new technology in Khayelitsha, South Africa, in collaboration with the University of Cape Town and the Foundation for Innovative New Diagnostics (FIND) and has implemented more than 30 analyzers to date. Globally, at the end of April 2011 at least 22 countries were already implementing GeneXpert MTB/ RIF and plans were in place to procure instruments and cartridges for 34 countries (25, 26) .
Malaria
In 2009, 225 million cases of malaria were estimated and caused an estimated 781,000 deaths, mostly among African children (27) . Malaria is responsible for 20 % of all childhood deaths. Microscopy is the reference standard for diagnosing malaria but requires considerable training and experience and is time consuming in high case load settings (28, 29) ( Figure  1D) . Therefore, LFIs, often called rapid diagnostic tests (RDTs), are a commonly used alternative as they are fast and easy to carry out, and provide reliable results (29 -33) (Figure  2A, B) .
MSF programs commonly use malaria RDTs to diagnose acute malaria infection. Three-line malaria tests Plasmodium falciparum (P.f.) /Pan tests are used in MSF programs where both P.f. and non-falciparum malaria species (i.e., Plasmodium ovale, Plasmodium malaria and Plasmodium vivax ) are present and two-line malaria tests, where P.f. is dominant. In 2010, MSF procured 6.5 million malaria RDTs.
Case study: sleeping sickness
Sleeping sickness or human African trypanosomiasis (HAT), transmitted by tsetse fl ies, occurs in 36 sub-Saharan African countries. Affected populations live in remote areas with very limited access to health care which hampers the diagnosis and treatment. During epidemic periods the prevalence can reach up to 50 % . The estimated number of actual cases was 30,000 in 2009 (34 -36) . Most cases were reported in the Democratic Republic of Congo and the Central African Republic where MSF has diagnosis and treatment programs (34 -36) .
The fi rst stage of the disease, also called the hemolytic phase, is characterized by fever, headaches, joint pain and itching due to the trypanosomes multiplying in the subcuteanous tissue, blood and lymph system.
In the second stage, the neurological stage, the parasite crosses the blood-brain barrier and symptoms like sensory disturbances, confusion, poor coordination changes of behavior and changes in the sleep cycle appear. Without treatment the disease is fatal. Ideally diagnosis is made as early as possible to avoid diffi cult, risky and complicated treatment of the second stage (37) .
The complexity of diagnostic algorithms and protocols faced is exemplifi ed by the testing needs for sleeping sickness (Figure 3 ) (37, 38) . For the diagnosis of HAT, screening is carried out by using the card agglutination test for trypanosomiasis (CATT), followed by confi rmation tests detecting the Trypanosoma parasites microscopically. Confi rmation methods are parasite detection in lymph node aspirates and isolation of parasites from whole blood using capillary tube centrifugation (CTC) technique, also called the Woo test, and/ or mini-anion exchange centrifugation technique (mAECT) (39) . where mAECT is not available, treatment can be started on the basis of a CATT positive result in a 1:16 dilution (strong serological suspect), without parasitological confi rmation. Disease staging remains, of course, necessary for selecting the appropriate treatment. Besides the complexity of HAT diagnosis and the urgent need for simplifi ed diagnostic tools, one of the main problems regarding HAT diagnosis is access to an uninterrupted supply of diagnostic materials (39) .
Clinical chemistry in MSF
Clinical chemistry is mostly used when monitoring treatment side effects, e.g., in HIV or TB treatment programs. For the most part ' wet ' semi-automatic photometers such as the Humalyzer 2000 (Human, Wiesbaden, Germany) are used. Programs with low demand prefer opting for ' dry ' chemistry due to the maintenance and quality control needs of the analyzer, but the costs of using ' dry ' chemistry are high ( € 1 -€ 2 per test compared with a few cents when using ' wet ' methods). In MSF laboratories, the number of tests ordered for ' wet ' chemistry analyzers is much higher than for ' dry ' analyzers ( Figure 4 ). In 2010, MSF contemplated moving away from ' wet ' chemistry systems towards using ' dry ' chemistry systems, such as the Refl otron ® by Roche. A cost-calculation model showed that using only ' dry ' chemistry would mean a cost increase of more than 50 times, which is not fi nancially sustainable.
Quality control
MSF considers quality control (QC) for laboratory testing to be a high priority and has developed a QC protocol for microscopy that is more applicable to RLS than other approaches such as lot quality assurance sampling (LQAS). The MSF QC approach was designed to: (i) allow a small sample size to be feasible across all settings; (ii) enable reliable analysis; (iii) monitor both false-positive and false-negative results; and (iv) be applicable to all microscopy testing (40) . In 2010, MSF enrolled several laboratories in the sub-Saharan region in the international accredited profi ciency testing provided by the National Health Laboratory Services (NHLS) and National Institute of Communicable Diseases (NICD) in South Africa. Over time external QC has allowed improvement of performance in the different areas such as malaria, TB microscopy, biochemistry, hematology and CD4 testing.
Conclusions
Access to reliable diagnostic tools in humanitarian settings is a cornerstone of good quality medical humanitarian assistance. MSF ' s experience in reinforcing laboratory capacity over the last decade has shown that much can be done to improve diagnostic capacity, even in the most remote and unstable settings. However, the scope of the improvements depends largely on the extent to which diagnostic tools are developed with humanitarian settings in mind. Such settings often lack skilled health staff, have limited health budgets, are confronted with a high burden of infectious diseases with most patients accessing care at the primary care level, far from secondary or tertiary hospitals. Unless efforts are made to ensure that advances in diagnostic technology take into account the realities of RLS, they are likely to be irrelevant to the majority of patients who could benefi t.
